Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-008609

PRESIDENT AND CEO sold 12,500 shares at $20.83 ($260,320)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-03-17 Sale : show line 1 in the form 10b5-1 −12,500 $20.83 $260,320 990,392 I
Open-market sales · 12,500 sh · avg $20.83 · $260,320
Loading xslF345X05/form4-03192025_090346.xml…